Canada markets close in 6 hours 24 minutes

Nektar Therapeutics (ITH.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
1.6460+0.3070 (+22.93%)
As of 10:37AM CEST. Market open.
Currency in EUR

Valuation Measures4

Market Cap (intraday) 250.19M
Enterprise Value 76.75M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)3.02
Price/Book (mrq)2.01
Enterprise Value/Revenue 0.85
Enterprise Value/EBITDA -0.32

Trading Information

Stock Price History

Beta (5Y Monthly) 0.91
52-Week Change 383.98%
S&P500 52-Week Change 323.57%
52 Week High 31.6460
52 Week Low 30.3901
50-Day Moving Average 30.9510
200-Day Moving Average 30.6343

Share Statistics

Avg Vol (3 month) 32.08k
Avg Vol (10 day) 347
Shares Outstanding 5183.62M
Implied Shares Outstanding 6212.13M
Float 8163.11M
% Held by Insiders 11.10%
% Held by Institutions 166.32%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-128.37%

Management Effectiveness

Return on Assets (ttm)-15.25%
Return on Equity (ttm)-110.95%

Income Statement

Revenue (ttm)90.12M
Revenue Per Share (ttm)0.47
Quarterly Revenue Growth (yoy)8.50%
Gross Profit (ttm)N/A
EBITDA -127.41M
Net Income Avi to Common (ttm)-276.06M
Diluted EPS (ttm)-1.3500
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)303.62M
Total Cash Per Share (mrq)1.65
Total Debt (mrq)230.4M
Total Debt/Equity (mrq)175.90%
Current Ratio (mrq)6.45
Book Value Per Share (mrq)0.68

Cash Flow Statement

Operating Cash Flow (ttm)-192.61M
Levered Free Cash Flow (ttm)-63.63M